CMRA News and Press, Comera Life Sciences Holdings Inc. From 10/16/23

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQ...

WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4...

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA )...

2023-08-10 10:01:52 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q2 GAAP EPS of -$0.08. Revenue of $315M (+114.3% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.08, revenue of $315M

– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock...

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™...

2023-08-01 08:44:03 ET Life sciences company Comera Life Sciences Holdings ( NASDAQ: CMRA ) said on Tuesday that it is set to complete a $4.1M private placement of shares, and accompanying warrants. The company has executed a definitive agreement to complete the private p...

WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to com...

– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs – WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ...

2023-05-11 11:43:48 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q1 GAAP EPS of -$0.13. Revenue of $0.39M (-58.9% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.13, revenue of $0.39M